Abiomed says revenue from its Impella heart surgery system nearly doubled in 3rd quarter

Impella device helps boost Abiomed’s 3Q revenue

DANVERS, Mass. — Abiomed Inc. said Thursday its revenue grew 32 percent in the fiscal third quarter due to growing use and sales of its Impella heart surgery device.

The company said its revenue totaled about $22.8 million for the quarter, as sales of the Impella Cardiac Assist Device surged 81 percent to $15.9 million. U.S. Impella revenue more than doubled to $14.5 million.

According to Thomson Reuters, analysts expected Abiomed to report $22.7 million in revenue for the quarter ended Dec. 31.

The Impella system is used during surgery to treat heart failure. Surgeons can use it to implant a device that will keep a patient’s blood flowing during the operation. Abiomed said the system was used in surgeries on 425 patients during the third quarter, compared with 160 a year ago.

In the year-ago period, the company posted $17.3 million in total revenue. That included $8.8 million in Impella revenue, $6.7 million of which came from the U.S. In the most recent quarter, Abiomed said most of the revenue came from reorders from previous clients.

The company is scheduled to report its full third-quarter results on Feb. 4. Analysts expect Abiomed to book a loss of 17 cents per share.